赵玉娇;蔡路奎;王晓丹;席珏敏;陈俊英;潘玥;邱丽娟;姜黎明;孙强明;

• 1:中国医学科学院北京协和医学院医学生物学研究所云南省重大传染病疫苗研发重点实验室

摘要(Abstract)：

目的对CpG ODN候选佐剂IMB-AC5进行体外免疫刺激活性分析。方法以目前国外进入临床研究的两种CpG ODN佐剂序列(Coley 7909和Dynavax ISS1018)为对照,采用~3H-TDR法检测IMB-AC5刺激人外周血淋巴细胞(peripheral blood lymphocytes,PBLs)的增殖活性;流式细胞术分析CD19+B活化细胞表面CD69表达水平;ELISA法检测刺激后GEN细胞产生的IL-6和IFNα水平。结果 3种CpG ODN佐剂均能明显刺激人PBLs的增生,IMB-AC5刺激增生能力优于Dynavax ISS1018,略低于Coley 7909;IMB-AC5活化CD19+B细胞表面CD69表达水平与Coley7909相似,Dynavax ISS1018活化效果略低于前二者;3种CpG ODN佐剂体外活化树突状细胞水平差异较大,且呈明显的剂量依赖,IMB-AC5的最佳活化浓度范围为0.15~1.5μmol/L,Coley 7909的最佳活化浓度范围为<0.25μmol/L,活化效果均优于Dynavax ISS1018。结论 IMB-AC5可作为有效的疫苗候选佐剂,且不低于国外同类佐剂的体外免疫刺激活性。

关键词(KeyWords)： CpG ODN;佐剂;免疫刺激活性

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金面上项目(81171946);; 国家“十二五”“重大新药创制”科技重大专项(2012ZX09104-302);; 云南省科技厅社会发展科技计划项目(2011CA016);; 云南省自然科学基金项目(2012FB188);; 北京协和医院学生创新项目(33320140148);; 医学生物学研究所研究生创新基金(2014-018-004)

作者(Author): 赵玉娇;蔡路奎;王晓丹;席珏敏;陈俊英;潘玥;邱丽娟;姜黎明;孙强明;

Email:

DOI: 10.13200/j.cnki.cjb.001609

参考文献(References)：

• [1]MOGENSEN T H.Pathogen recognition and inflammatory signaling in innate immune defenses[J].Clin Microbiol Rev,2009,22(2):240-273.
• [2]KAWAI T,AKIRA S.The role of pattern-recognition receptors in innate immunity:update on Toll-like receptors[J].Nat Immunol,2010,11(5):373-384.
• [3]MONACI E,MANCINI F,LOFANO G,et al.MF59-and Al(OH)3-adjuvanted Staphylococcus aureus(4C-Staph)vaccines induce sustained protective humoral and cellular immune responses,with a critical role for effector CD4 T cells at low antibody titers[J].Front Immunol,2015,6(9):439-444.
• [4]KOBIYAMA K,AOSHI T,NARITA H,et al.Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist[J].Proc Natl Acad Sci USA,2014,111(8):3086-3091.
• [5]BODE C,ZHAO G,STEINHAGEN F,et al.CpG DNA as a vaccine adjuvant[J].Expert Rev Vaccines,2011,10(4):499-511.
• [6]SAMULOWITZ U,WEBER M,WEERATNA R,et al.A novel class of immune-stimulatory CpG oligodeoxynucleotides unifies high potency in type I interferon induction with preferred structural properties[J].Oligonucleotides,2010,20(2):93-101.
• [7]TOUGAN T,AOSHI T,COBAN C,et al.TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models[J].Hum Vaccin Immunother,2013,9(2):283-290.
• [8]KANZLER H,BARRAT F J,HESSEL E M,et al.Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists[J].Nat Med,2007,13(5):552-559.
• [9]OVERSTREET M G,FREYBERGER H,COCKBURN I A,et al.CpG-enhanced CD8+T-cell responses to peptide immunization are severely inhibited by B cells[J].Eur J Immunol,2010,40(1):124-133.
• [10]WEINER G J.The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides[J].J Leukoc Biol,2000,68(4):455-463.
• [11]ENG N F,BHARDWAJ N,MULLIGAN R,et al.The pote-ntial of 1018 ISS adjuvant in hepatitis B vaccines:HEPLISAVTM review[J].Hum Vaccin Immunother,2013,9(8):1661-1672.
• [12]COOPER C,MACKIE D.Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine:a review of HEPLISAVTMsafety and efficacy[J].Expert Rev Vaccines,2011,10(4):417-427.
• [13]COOPER C L,DAVIS H L,MORRIS M L,et al.CPG 7909,an immunostimulatory TLR9 agonist oligodeoxynucleotide,as adjuvant to Engerix-B HBV vaccine in healthy adults:a double-blind phase I/II study[J].J Clin Immunl,2004,24(6):693-701.